La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BioPorto Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di BioPorto diminuiranno del 35% all'anno, mentre si prevede che il fatturato annuo crescerà del 29.2% all'anno. Si prevede che l'EPS diminuirà del 24.6% all'anno.

Informazioni chiave

-35.0%

Tasso di crescita degli utili

-24.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	35.4%
Tasso di crescita dei ricavi	29.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	23 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Previsioni di crescita degli utili e dei ricavi

CPSE:BIOPOR - Stime future degli analisti e dati finanziari passati (DKK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	52	-90	N/A	N/A	1
12/31/2024	40	-73	N/A	N/A	1
6/30/2024	34	-50	-56	-56	N/A
3/31/2024	32	-54	-50	-50	N/A
12/31/2023	31	-56	-55	-55	N/A
9/30/2023	33	-70	-69	-69	N/A
6/30/2023	30	-78	-63	-63	N/A
3/31/2023	31	-75	-62	-62	N/A
12/31/2022	29	-76	-53	-52	N/A
9/30/2022	27	-68	-51	-51	N/A
6/30/2022	27	-62	-59	-58	N/A
3/31/2022	25	-59	-61	-60	N/A
12/31/2021	24	-57	-65	-65	N/A
9/30/2021	25	-54	-59	-58	N/A
6/30/2021	24	-60	-48	-47	N/A
3/31/2021	25	-62	-44	-43	N/A
12/31/2020	23	-62	-37	-36	N/A
9/30/2020	22	-64	-43	-42	N/A
6/30/2020	24	-68	-55	-55	N/A
3/31/2020	25	-69	-62	-61	N/A
12/31/2019	27	-70	-61	-60	N/A
9/30/2019	29	-61	-53	-51	N/A
6/30/2019	28	-51	-45	-44	N/A
3/31/2019	27	-43	-40	-39	N/A
12/31/2018	26	-38	-39	-38	N/A
9/30/2018	24	-38	-40	-39	N/A
6/30/2018	25	-36	-38	-38	N/A
3/31/2018	24	-35	N/A	-36	N/A
12/31/2017	25	-32	N/A	-29	N/A
9/30/2017	25	-29	N/A	-26	N/A
6/30/2017	23	-27	N/A	-25	N/A
3/31/2017	21	-26	N/A	-21	N/A
12/31/2016	21	-23	N/A	-20	N/A
9/30/2016	20	-21	N/A	-21	N/A
6/30/2016	20	-16	N/A	-20	N/A
3/31/2016	21	-12	N/A	-18	N/A
12/31/2015	20	-11	N/A	-17	N/A
9/30/2015	20	-11	N/A	-15	N/A
6/30/2015	19	-12	N/A	-14	N/A
3/31/2015	18	-13	N/A	-14	N/A
12/31/2014	19	-13	N/A	-16	N/A
9/30/2014	18	-15	N/A	-14	N/A
6/30/2014	19	-19	N/A	-16	N/A
3/31/2014	18	-20	N/A	-17	N/A
12/31/2013	17	-22	N/A	-17	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che BIOPOR rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che BIOPOR rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che BIOPOR rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di BIOPOR ( 29.2% all'anno) crescerà più rapidamente del mercato Danish ( 11% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di BIOPOR ( 29.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di BIOPOR è previsto essere elevato tra 3 anni

BioPorto Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 80%

Bioporto A/S Affirms Earnings Guidance for 2024

Bioporto A/S Provides Revenue Guidance for 2024

Consensus estimates of losses per share improve by 16%

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

BioPorto A/S Maintains Earnings Guidance for the Year 2023

Recent updates

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully